Tumor Necrosis Factor and Its Blockade in Granulomatous Infections: Differential Modes of Action of Infliximab and Etanercept?
Open Access
- 1 August 2005
- journal article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 41 (Supplement), S199-S203
- https://doi.org/10.1086/429998
Abstract
Tumor necrosis factor (TNF) is a critical component of both the antibacterially protective and the inflammatory responses against infections, particularly infections with intracellularly viable microorganisms. It is, therefore, not surprising that some treatment regimens that target TNF function have resulted in an increase in complications associated with infections due to such pathogens as Mycobacterium tuberculosis, Listeria monocytogenes, and Histoplasma capsulatum; organized granuloma formation is required to keep such infections under control. However, treatment with anti-TNF monoclonal antibodies (i.e., infliximab) has been associated with a higher incidence of granulomatous infections than has treatment with a TNF receptor (TNFR) p75 immunoglobulin G—fusion construct (i.e., etanercept). Three hypotheses concerning the mode of action of these 2 agents that might explain this difference are discussed here: differential induction of apoptosis or lysis in membrane TNF—expressing macrophages and T cells, differential inhibition of signaling via TNFRp55 and TNFRp75, and different net neutralizing capacities resulting from different pharmacologic properties.Keywords
This publication has 32 references indexed in Scilit:
- Granulomatous Infectious Diseases Associated with Tumor Necrosis Factor AntagonistsClinical Infectious Diseases, 2004
- The therapeutic potential of TNF-α blockade in rheumatoid arthritisExpert Opinion on Investigational Drugs, 2003
- Tumor necrosis factor signalingCell Death & Differentiation, 2003
- Life‐threatening histoplasmosis complicating immunotherapy with tumor necrosis factor α antagonists infliximab and etanerceptArthritis & Rheumatism, 2002
- Safety and Efficacy of Disease-Modifying Anti-Rheumatic AgentsDrug Safety, 2002
- Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing AgentNew England Journal of Medicine, 2001
- Tumor necrosis factor α antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitisGastroenterology, 1999
- Tumor necrosis factor-α is required in the protective immune response against mycobacterium tuberculosis in miceImmunity, 1995
- Chimeric anti-TNF-α monoclonal antibody cA2 binds recombinant transmembrane TNF-α and activates immune effector functionsCytokine, 1995
- The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infectionCell, 1989